Ziprasidone metabolism, aldehyde oxidase, and clinical implications

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 229-232

  Beedham, Christine ^a   Miceli, Jeffrey J ^b   Obach, R Scott ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ALCOHOL; ALDEHYDE DEHYDROGENASE; ALDEHYDE OXIDASE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DISULFIRAM; FAMCICLOVIR; KETOCONAZOLE; MENADIONE; METHADONE; MOLYBDENUM; PENCICLOVIR; PROADIFEN; VITAMIN K GROUP; XENOBIOTIC AGENT; ZALEPLON; ZIPRASIDONE; ZONISAMIDE;

ALCOHOL METABOLISM; ARTICLE; DNA POLYMORPHISM; DRUG ALCOHOL INTERACTION; DRUG INDICATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; LIPID BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; QT INTERVAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PIPERAZINES; THIAZOLES;

EID: 0038722339     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306000-00003     Document Type: Article

References (32)

1. Schmidt AW, Lebel LA, Howard HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
2. Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Op Pharmacother. 2001;2:571-582.
3. Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psych. 2001;62:347-349.
4. Food and Drug Administration Psychopharmacological Drugs Advisory Committee. Briefing Document for Zeldox Capsules (Ziprasidone HCl). July 19, 2000. Available at http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619bla.pdf. Accessed July 10, 2002.
5. Prakash C, Kamel A, Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Met Disp. 1997;25:863-872.
6. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol. 1998;38:389-430.
7. Prakash C, Kamel A, Cui D, et al., Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000;49:(Suppl 1):35S-42S.
8. Miceli JJ, Smith M, Robarge L, et al. The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(Suppl 1):71S-76S.
9. Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49(Suppl 1):65S-70S.
10. Kamel A, Prakash C, Obach S. Determination of the enzymes involved in the reductive cleavage of ziprasidone to dihydroziprasidone and the formation of S-methyldihydroziprasidone using human in vitro systems and electrospray ionisation tandem mass spectrometry (ESI/MS/MS). In: Proceedings of the 50th ASMS Conference (Orlando, Florida). 2002. Abstract available at http://www.inmerge.com/aspfolder/ASMSarchresults.asp
11. Rajagopalan KV, Fridovich I, Handler P. Hepatic aldehyde oxidase. I. Purification and properties. J Biol Chem. 1962;237:922-928.
12. Beedham C. Oxidation at carbon via molybdenum hydroxylases. In: Gooderham NJ, ed. Drug Metabolism Towards the Next Millenium. IOS Press: Ohmsha; 1998:39-52.
13. Beedham C. Molybdenum hydroxylases. In: Ioannides C, ed. Enzyme Systems That Metabolise Drugs and Other Xenobiotics. New York: John Wiley & Sons, Ltd.; 2002:48-187.
14. Rashidi MR, Smith JA, Clarke SE, et al. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Met Disp. 1997;25:805-813.
15. Kawashima K, Hosoi K, Naruke T, et al. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Met Disp. 1999;27:422-428.
16. Sugihara K, Kitamura S, Tatsumi K. Involvement of mammalian liver cytosol and aldehyde oxidase in reductive metabolism of zonisamide. Drug Met Disp. 1996;24:199-202.
17. Schofield PC, Robertson IGC, Paxton JW. Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl] acridine-4-carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol. 2000;59:161-165.
18. Yoshihara S, Tatsumi K. Kinetic and inhibition studies on reduction of diphenylsulphoxide by guinea pig liver aldehyde oxidase. Arch Biochem Biophys. 1986;249:8-14.
19. Rashidi MR, Smith JA, Clarke SE, et al. Inhibition of human and guinea-pig liver aldehyde oxidase in-vitro. J Pharm Pharmacol. 1995;47:1090.
20. Robertson GC, Gamage RSKA. Methadone: a potent inhibitor of rat liver aldehyde oxidase. Biochem Pharmacol. 1994;47:584-587.
21. Robertson IGC, Bland TJ. Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993;45:2159-2162.
22. Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision cut liver slices. Xenobiotica. 2002;32:849-862.
23. Bonate PL, Reith K, Weir S. Drug interactions at the renal level: implications for drug development. Clin Pharmacokinet. 1998;34:375-404.
24. Knodell RG, Holtzman JL, Crankshaw DL, et al. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterol. 1982;82:84-88.
25. Wilner KD, Hansen RA, Folger CJ, et al. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol. 2000;49(Suppl 1):61S-64S.
26. Pratt SK, Fowles SE, Pierce DM, et al. An investigation of the potential interaction between cimetidine and famciclovir in non-patient volunteers. Br J Clin Pharmacol. 1991;32:656P-657P.
27. Klyosov AA. Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochem 1996;35:4457-4467.
28. Johns DG. Human liver aldehyde oxidase: differential inhibition and oxidation of charged and uncharged substrates. J Clin Invest. 1967;46:1492-1505.
29. Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Molecular Biol. 1992;27:283-335.
30. Helander A, Walzer C, Beck O, et al. Influence of genetic variation in alcohol and aldehyde dehydrogenase on serotonin metabolism. Life Sciences 1994;55:359-366.
31. Kitson KE, Weiner H. Ethanol and acetaldehyde metabolism: past, present, and future alcohol. Clin Exp Res. 1996;20:A82-A92.
32. Peterson EN. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psych Scand. 1992;86(Suppl 369):7-13.